Showing 1241-1250 of 1414 results for "".
- LumiThera Purchases MacuLogix Assetshttps://modernod.com/news/lumithera-purchases-maculogix-assets/2481007/LumiThera announced the purchase of the assets of MacuLogix. Terms of the deal were not disclosed. MacuLogix is the developer of the wearable AdaptDX Pro dark adaptometer, which allows eye care professionals to measure dark adaptation—designed to dia
- Nanodropper Announces Growth in Partnerships and Availabilityhttps://modernod.com/news/nanodropper-announces-increases-in-partnerships-and-availability/2480921/Nanodropper, a volume-reducing adaptor for eye drop bottles, announced major growth over the last 12 months, including an 832% increase in clinic partnerships, expanding to more than 840 clinic locations since June of 2021. Nanodropper has also more than doubled its team as it finalized rese
- Lensar Submits FDA 510(k) Application for ALLYhttps://modernod.com/news/lensar-announces-us-food-and-drug-administration-acceptance-of-510k-submission-for-ally/2480671/Lensar announced that the FDA has accepted its 510(k) submission for its next-generation ALLY Adaptive Cataract Treatment System for review. The submission is the first stage of a planned, two-step commercial release s
- Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 Granted Orphan Drug Designation by EMAhttps://modernod.com/news/neurophth-therapeutics-treatment-of-lebers-hereditary-optic-neuropathy-gene-therapy-nr082-granted-orphan-drug-designation-by-ema/2480605/Neurophth Therapeutics announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) granted the orphan drug designation (ODD) for the company's leading gene therapy drug candidate, NR082 (rAAV2-ND4), for the treatment of Leber's hereditary opt
- Nanodropper and Lumata Health Launch Partnership Aimed at Improving Patient Carehttps://modernod.com/news/nanodropper-and-lumata-health-launch-partnership-aimed-at-improving-patient-care/2480600/Nanodropper recently announced a partnership with Lumata Health, which includes the launch of a pilot program bringing the Nanodropper Adaptor device to Lumata Health network patients across the United States. Lumata Health is a tech-enabled health care service company fo
- Mitotech Granted Orphan Drug Designation by FDA for Visomitin in LHONhttps://modernod.com/news/mitotech-granted-orphan-drug-designation-by-fda-for-visomitin-in-lhon/2480520/Luxembourg-based Mitotech SA announced that the FDA has granted orphan drug designation (ODD) for the company’s topical cardiolipin peroxidation inhibitor, Visomitin, for the treatment of Leber’s Hereditary Optic Neuropathy (LHON), a rare inherited condition that can lead to blin
- Heru Releases re:Vive 2.0: A Single Wearable Platform with 6 Vision Diagnostic Modalities that Support 5 CPT Codeshttps://modernod.com/news/heru-releases-revive-20-a-single-wearable-platform-with-6-vision-diagnostic-modalities-that-support-5-cpt-codes/2480396/Heru announced it is expanding the capabilities of re:Vive by Heru, the company’s wearable gamified diagnostic solution, to include three new testing modalities: Color Vision CPT 92283, Contrast Sensitivity, and Dark Adaptation CPT 92284. “Since the inception of Heru, our go
- AMA: Look to Ophthalmology for a Glimpse of Telemedicine’s Futurehttps://modernod.com/news/ama-look-to-ophthalmology-for-a-glimpse-of-telemedicines-future/2479477/Early on in the COVID-19 pandemic, ophthalmology struggled to adapt to telemedicine. It just wasn’t set up for virtual visits. “Ophthalmology is an exam-heavy specialty, and we really rely on all the clinical clues that we capture—either at the slit lamp, or looking at the retina, or check
- At-Home App Helps Patients Stay Engaged and Adherent to Vision Monitoring Remotelyhttps://modernod.com/news/at-home-app-helps-patients-stay-engaged-and-adherent-to-vision-monitoring-remotely/2479208/Novartis announced it has begun a US pilot program for OdySight, a clinically tested mobile application designed to help monitor vision remotely. Recent changes to public health protocols, paired with a growing patient population and existing treatment burden, have placed an emphasis on vi
- Mount Sinai Ophthalmologists use Breakthrough Imaging to Understand Eye Damage from Rare Congenital Retinal Diseasehttps://modernod.com/news/mount-sinai-ophthalmologists-use-breakthrough-imaging-to-understand-eye-damage-from-rare-congenital-retinal-disease/2479098/Researchers from New York Eye and Ear Infirmary of Mount Sinai used adaptive optics–retinal imaging technology that allows clinicians to examine microscopic structures of the eye in living patients with extreme detail in real time–to analyze and better understand a rare retinal disease called “fu